Rhythm Pharmaceuticals highlights IMCIVREE launch progress in acquired hypothalamic obesity presentation

Rhythm Pharmaceuticals highlighted IMCIVREE’s U.S. launch for acquired hypothalamic obesity following FDA clearance on March 19, 2026.

Japan launch is anticipated by year-end 2026, while European country launches are expected to begin in 2027 following European Commission authorization.

Early U.S. uptake included more than 400 patient start forms in the first 14 weeks and about 300 unique prescribers.

Cash, cash equivalents and short-term investments totaled $330.9 million as of June 30, 2026, with 68.6 million common shares outstanding.

Pipeline milestones include a year-end 2026 start of a pivotal Phase 3 trial of oral bivamelagon in acquired hypothalamic obesity.